Fibrillar amyloid correlates of preclinical cognitive decline

Alzheimer's and Dementia

Volumn 10, Issue 1, 2014, Pages

  Stonnington, Cynthia M ^a   Chen, Kewei ^b   Lee, Wendy ^b   Locke, Dona E C ^a   Dueck, Amylou C ^a   Liu, Xiaofen ^b   Roontiva, Auttawut ^b   Fleisher, Adam S ^b,c   Caselli, Richard J ^a   Reiman, Eric M ^b  

^a MAYO CLINIC   (United States)

^b BANNER ALZHEIMER S INSTITUTE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Alzheimer's disease; Amyloid imaging; Apolipoprotein E; Cognitive decline; Preclinical

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E4; PITTSBURGH COMPOUND B;

ADULT; AGED; ARTICLE; BRAIN MAPPING; BRAIN RADIOGRAPHY; COGNITIVE DEFECT; CONTROLLED STUDY; CORRELATIONAL STUDY; DISTRIBUTION VOLUME; DRUG DISTRIBUTION; EDUCATIONAL STATUS; EXECUTIVE FUNCTION; FEMALE; FOLLOW UP; GENE DOSAGE; GENOTYPE; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MEMORY; MIDDLE AGED; NEUROPSYCHOLOGICAL TEST; OBSERVATIONAL STUDY; PET SCANNER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; TISSUE DISTRIBUTION;

ALZHEIMER'S DISEASE; AMYLOID IMAGING; APOLIPOPROTEIN E; COGNITIVE DECLINE; PRECLINICAL;

AGED; AMYLOID; ANILINE COMPOUNDS; APOLIPOPROTEIN E4; BRAIN; BRAIN MAPPING; COGNITION DISORDERS; FEMALE; HUMANS; MALE; MEMORY DISORDERS; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; OBSERVATION; POSITRON-EMISSION TOMOGRAPHY; PROSPECTIVE STUDIES; THIAZOLES;

EID: 84891148129     PISSN: 15525260     EISSN: 15525279     Source Type: Journal    
DOI: 10.1016/j.jalz.2013.01.009     Document Type: Article

References (26)

1. R.A. Sperling, P.S. Aisen, L.A. Beckett, D.A. Bennett, S. Craft, and Am Fagan et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease Alzheimers Dement 7 2011 280 292
2. R.J. Caselli, E.M. Reiman, D.E. Locke, M.L. Hutton, J.G. Hentz, and C. Hoffman-Snyder et al. Cognitive domain decline in healthy apolipoprotein E epsilon4 homozygotes before the diagnosis of mild cognitive impairment Arch Neurol 64 2007 1306 1311 (Pubitemid 47403086)
3. R.J. Caselli, A.C. Dueck, D. Osborne, M.N. Sabbagh, D.J. Connor, and G.L. Ahern et al. Longitudinal modeling of age-related memory decline and the APOE epsilon4 effect N Engl J Med 361 2009 255 263
4. R.J. Caselli, K. Chen, W. Lee, G.E. Alexander, and E.M. Reiman Correlating cerebral hypometabolism with future memory decline in subsequent converters to amnestic pre-mild cognitive impairment Arch Neurol 65 2008 1231 1236
5. W.E. Klunk, H. Engler, A. Nordberg, Y. Wang, G. Blomqvist, and D.P. Holt et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B Ann Neurol 55 2004 306 319 (Pubitemid 38269583)
6. J. Lister-James, M.J. Pontecorvo, C. Clark, A.D. Joshi, M.A. Mintun, and W. Zhang et al. Florbetapir f-18: a histopathologically validated Beta-amyloid positron emission tomography imaging agent Semin Nucl Med 41 2011 300 304
7. C.R. Jack Jr., D.S. Knopman, S.D. Weigand, H.J. Wiste, P. Vemuri, and V. Lowe et al. An operational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer disease Ann Neurol 71 2012 765 775
8. R.J. Bateman, C. Xiong, T.L. Benzinger, A.M. Fagan, A. Goate, and N.C. Fox et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease N Engl J Med 367 2012 795 804
9. P.M. Doraiswamy, R.A. Sperling, R.E. Coleman, K.A. Johnson, E.M. Reiman, and M.D. Davis et al. Amyloid-beta assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study Neurology 79 2012 1636 1644
10. E.M. Reiman, K. Chen, X. Liu, D. Bandy, M. Yu, and W. Lee et al. Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease Proc Natl Acad Sci U S A 106 2009 6820 6825
11. K. Kantarci, V. Lowe, S.A. Przybelski, S.D. Weigand, M.L. Senjem, and R.J. Ivnik et al. APOE modifies the association between Aβ load and cognition in cognitively normal older adults Neurology 78 2012 232 240
12. R.J. Caselli, E.M. Reiman, D. Osborne, J.G. Hentz, L.D. Baxter, and J.L. Hernandez et al. Longitudinal changes in cognition and behavior in asymptomatic carriers of the APOE e4 allele Neurology 62 2004 1990 1995 (Pubitemid 38738209)
13. J.E. Hixson, and D.T. Vernier Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI J Lipid Res 31 1990 545 548 (Pubitemid 20107994)
14. R.C. Petersen, J.C. Stevens, M. Ganguli, E.G. Tangalos, J.L. Cummings, and S.T. DeKosky Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology Neurology 56 2001 1133 1142
15. G. McKhann, D. Drachman, M. Folstein, R. Katzman, D. Price, and E.M. Stadlan Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease Neurology 34 1984 939 944 (Pubitemid 14076461)
16. R.L. Spitzer, J.B.W. Williams, M. Gibbon, and M.B. First Structured clinical interview for DSM-III-R, patient edition/non-patient edition (SCID-P/SCID-NP) 1990 American Psychological Association Washington, DC
17. J. Talairach, and P. Tournoux Co-planar stereotaxic atlas of the human brain 1988 Thieme New York
18. Y.Y. Lim, K.A. Ellis, R.H. Pietrzak, D. Ames, D. Darby, and K. Harrington et al. Stronger effect of amyloid load than APOE genotype on cognitive decline in healthy older adults Neurology 79 2012 1645 1652
19. D.G. Darby, A. Brodtmann, R.H. Pietrzak, J. Fredrickson, M. Woodward, and V.L. Villemagne et al. Episodic memory decline predicts cortical amyloid status in community-dwelling older adults J Alzheimers Dis 27 2011 627 637
20. M. Storandt, M.A. Mintun, D. Head, and J.C. Morris Cognitive decline and brain volume loss as signatures of cerebral amyloid-beta peptide deposition identified with Pittsburgh compound B: cognitive decline associated with Abeta deposition Arch Neurol 66 2009 1476 1481
21. N.J. Cairns, M.D. Ikonomovic, T. Benzinger, M. Storandt, A.M. Fagan, and A.R. Shah et al. Absence of Pittsburgh compound B detection of cerebral amyloid beta in a patient with clinical, cognitive, and cerebrospinal fluid markers of Alzheimer disease: a case report Arch Neurol 66 2009 1557 1562
22. G. Chetelat, V.L. Villemagne, K.E. Pike, K.A. Ellis, P. Bourgeat, and G. Jones et al. Independent contribution of temporal beta-amyloid deposition to memory decline in the pre-dementia phase of Alzheimer's disease Brain 134 2011 798 807
23. J.V. Ly, G.A. Donnan, V.L. Villemagne, J.A. Zavala, H. Ma, and G. O'Keefe et al. 11C-PIB binding is increased in patients with cerebral amyloid angiopathy-related hemorrhage Neurology 74 2010 487 493
24. H. Quigley, S.J. Colloby, and J.T. O'Brien PET imaging of brain amyloid in dementia: a review Int J Geriatr Psychiatry 26 2011 991 999
25. O. Pedraza, G.E. Smith, R.J. Ivnik, F.B. Willis, T.J. Ferman, and R.C. Petersen et al. Reliable change on the Dementia Rating Scale J Int Neuropsychol Soc 13 2007 716 720 (Pubitemid 350017947)
26. B.C. Sachs, J.A. Lucas, G.E. Smith, R.J. Ivnik, R.C. Petersen, and N.R. Graff-Radford et al. Reliable change on the Boston naming test J Int Neuropsychol Soc 18 2012 375 378